Tech Tuesday: We’ve got the latest tech from Purdue at your fingertips

Available-to-license innovations from the Office of Technology Commercialization

Every day the Purdue Research Foundation Office of Technology Commercialization receives and reviews invention disclosures from Purdue University researchers across all campuses and academic disciplines.

Here are the newest innovations available for licensing or optioning, developing and commercializing. Each entry includes the innovation’s reference number, title, summary, domain, Technology Readiness Level, and business development manager’s name and email address. TRLs assess the maturity level of a technology: 1 is the lowest, 9 is the highest.



VR Training for cryoEM: Gatan CP3

Summary: Researchers at Purdue University have developed a virtual reality training software to teach users to operate the Gatan CP3 system. This technology allows users to become trained on equipment without the high financial constraints associated with using cryoEM equipment. This technology also offers organizations a chance to decrease the machine time that must be set aside for training, as much of a user’s training could be completed in a VR environment.

Domain 1: Biomedical Engineering

Domain 2: Computer Technology

TRL: 9

Business Development Manager: Matt Halladay,


Treatment of Lowe Syndrome with Repurposed Drugs

Summary: Researchers at Purdue University have developed a therapeutic strategy for Lowe Syndrome, a currently untreatable genetic disorder characterized by cognitive deficiencies, bilateral congenital cataracts and renal dysfunction that leads to the early death of those affected, often from kidney failure. The Purdue treatment method has the potential to reverse symptoms and offer patients a higher quality of life. The researchers designed this treatment regimen using rapamycin and statins, drugs approved by the FDA for other indications because of on those drugs’ ability to target two molecular pathways implicated in Lowe Syndrom.

Domain: Pharmaceuticals

Business Development Manager: Joseph Kasper,

TRL: 3


Cancer Therapy Using an Immunoactive Nanocarrier of Immunogenic Cell Death Inducers

Summary: Purdue University researchers have developed a nanoparticle delivery system to enhance the efficacy of immunogenic cell death (ICD) inducing cancer drugs. ICD inducers are being used to improve the scope of immune checkpoint blockade therapy, which is effective in as few as 20% of patients for some cancer types. Unfortunately, traditional ICD inducers are limited by their immunotoxicity and insufficient adjuvanticity. The Purdue researchers designed a nanoparticle drug carrier to address these shortcomings. This technology encapsulates ICD inducers in functionalized nanoparticles. The nanoparticles are designed to release the ICD inducers in a sustained manner, and the nanoparticles are functionalized with a chemoattractive agent to recruit immune cells and prevent an immunosuppressive microenvironment.

Domain 1: Biotechnology

Domain 2: Pharmaceuticals

Business Development Manager: Joseph Kasper,

TRL: 2


Deterministic Creation of Single Photon Emitting Interface Emitters

Summary: Researchers at Purdue University have developed a method for the deterministic creation of single-photon emitters. This method offers a solution to one of the primary limitations in this field, as it is highly scalable and capable of producing millions to billions of single-photon emitters on a standard wafer with subwavelength accuracy. Potential applications of this technology include quantum information technology, communications, sensing and security.

Domain 1: Electrical Engineering

Domain 2: Micro & Nanotechnologies

Business Development Manager: Will Buchanan,

TRL: 2


Hybrid Mass-Alpha Spectrometry for High-Resolution Spectroscopy

Summary: Researchers at Purdue University have developed a new spectroscopic method for detecting trace amounts of alpha-emitting radionuclides. Traditionally, detecting closely spaced energetic alpha radiation-emitting isotopes at trace concentrations needing mass spectrometry has taken weeks. On the other hand, the Purdue hybrid technology rapidly and spectroscopically detects alpha radiation with ~100% sensitivity, less than 10 keV resolution, and an accuracy within 5% when evaluated against standards.

Domain: Chemistry and Chemical Analysis

Business Development Manager: Will Buchanan,

TRL: 2

A complete list of innovations available at the Purdue Research Foundation Office of Technology Commercialization is available online.